After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug

Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.

court house

Gilead Sciences Inc. is once again in the middle of a high stakes patent brawl as ViiV Healthcare claims Gilead's new HIV combination therapy Biktarvy (BIC/TAF) is insubstantially different from ViiV's dolutegravir.

ViiV filed a patent infringement suit against Gilead in the US District Court for the District of Delaware on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet